SGM
BCAX

Seven Grand Managers’s Bicara Therapeutics BCAX Stock Holding History

Seven Grand Managers’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.24M Buy
+62,500
New +$1.08M 0.08% 142

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Seven Grand Managers's BCAX Position: Q1 2026 in Review

Seven Grand Managers opened a new position in Bicara Therapeutics (BCAX) in Q1 2026: 62,500 shares worth $1.24M. The stake represents 0.08% of the portfolio and ranks #142 among its holdings.

146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Seven Grand Managers held 62,500 shares of Bicara Therapeutics worth $1.24M as of Q1 2026.
  • Bicara Therapeutics was a new Seven Grand Managers position in Q1 2026.
  • Bicara Therapeutics made up 0.08% of Seven Grand Managers's portfolio in Q1 2026, its #142 holding.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Seven Grand Managers's 13F filing for Q1 2026, filed 6 May 2026.